Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes

Farooq, Muhammad Asim; Huang, Xinyu; Jabeen, Amna; Ahsan, Anam; Seidu, Theodora Amanda; Kutoka, Perpetua Takunda; Wang, Bo

doi:10.1016/j.colsurfb.2020.111523

Cited by 47 publications

(23 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For cytotoxicity assays using nanoparticles, regularly breast cancer cells are used. However, it has already been shown that cancer lines such as MCF-7 can be induced apoptosis with nanoparticles, and the same nanomaterial does not present any cytotoxic effect in non-cancer lines such as MCF-12F and MCF-10A [ 46 , 47 ]. In a recent study, the fibroblasts exposed to biosynthesized copper nanoparticles displayed uniform growth and normal morphology, reflecting good biocompatibility [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

Highly Antifungal Activity of Biosynthesized Copper Oxide Nanoparticles against Candida albicans

García-Marín

Juárez-Moreno²,

Castro-Longoria

2022

Nanomaterials

View full text Add to dashboard Cite

Candida albicans (ATCC SC5314) was exposed to biosynthesized copper oxide nanoparticles (CuONPs) to determine their inhibitory capacity. Nanoparticles were polydisperse of small size (5.8 ± 3.5 nm) with irregular shape. The minimum inhibitory concentration (MIC) against C. albicans was 35.5 µg/mL. The production of reactive oxygen species (ROS) of C. albicans was verified when exposed to different concentrations of CuONPs. Ultrastructural analysis of C. albicans revealed a high concentration of CuONPs in the cytoplasm and outside the cell; also, nanoparticles were detected within the cell wall. Cytotoxic analyses using fibroblasts (L929), macrophages (RAW 264.7), and breast (MCF-12) cell lines show good results of cell viability when exposed at the MIC. Additionally, a hemocompatibility analysis was carried out and was found to be below 5%, considered the threshold for biocompatibility. Therefore, it is concluded that the biosynthesized CuONPs have a high potential for developing a topical antifungal treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Highly Antifungal Activity of Biosynthesized Copper Oxide Nanoparticles against Candida albicans

García-Marín

Juárez-Moreno²,

Castro-Longoria

2022

Nanomaterials

View full text Add to dashboard Cite

show abstract

“…The PEG molecule could form a molecular barrier on the surface of liposomes, which could improve the stability of the liposomes. [60][61][62] The leakage rate of ES-SSL-OXA at 48 h was the lowest, which was only about 13% of its original encapsulation efficiency. When the OXA liposomes were stored at 4°C (Figure 4A) for 24 h and 48 h, the leakage rate of the four liposomal formulations was less than 10%, indicating the liposome preparations were more stable at 4°C.…”

Section: Drug Release Studymentioning

confidence: 97%

In vitro and in vivo Evaluation of a Novel Estrogen-Targeted PEGylated Oxaliplatin Liposome for Gastric Cancer

Sun¹,

Xie²,

Tang³

et al. 2021

IJN

View full text Add to dashboard Cite

Background: Chemotherapy is still the main first-line treatment for advanced metastatic gastric cancer, but it has the limitations of serious side effects and drug resistance. Conventional liposome has been substantially used as drug carriers, but they lack targeting character with lower drug bioavailability in tumor tissues. Based on the above problems, a novel estrogentargeted PEGylated liposome loaded with oxaliplatin (ES-SSL-OXA) was prepared to further improve the metabolic behavior, the safety profile, and the anti-tumor efficacy of oxaliplatin. Methods: Four kinds of oxaliplatin (OXA) liposomes were prepared by film hydration method. The obtained formulations were characterized in terms of entrapment efficiency (EE), particle size, and so on by HPLC and DLS (dynamic light scanning). The morphology of ES-SSL-OXA was detected by transmission electron microscope (TEM). The in vitro and in vivo targeting effect of ES-SSL-OXA was verified by fluorescence microscopy and in vivo imaging system in gastric cancer cells (SGC-7901) and tumor-bearing athymic mice. The in vitro and in vivo antitumor efficacies of ES-SSL-OXA were investigated on SGC-7901 cells and athymic tumor-bearing mice. Pharmacokinetic, biodistribution, and acute toxicity tests of ES-SSL-OXA were performed on ICR mice. Results:The ES-SSL-OXA exhibited an average particle size of about 153.37 nm with an encapsulation efficiency of 46.20% and low leakage rates at 4°C and 25°C. In vivo and in vitro targeting study confirmed that ES-SSL-OXA could effectively target the tumor site. The antitumor activity demonstrated the strongest inhibition in tumor growth of ES-SSL-OXA. Pharmacokinetics and acute toxicity study showed that ES-SSL-OXA could significantly improve the metabolic behavior and toxicity profile of oxaliplatin. Conclusion:In this study, a novel estrogen-targeted long-acting liposomal formulation of OXA was successfully prepared. ES fragment effectively targeted the delivery system to tumor tissues which highly express estrogen receptor, providing a promising therapeutic method for gastric cancer in clinic.

show abstract

“…The physicochemical properties of the compound were modified via incorporating into the TPGS‐coated liposomal structure, where stable structure with sustained release profile depicted enhanced uptake by the BC cells with superior cytotoxicity when compared to free drug. [ 162 ] In a similar concept, iodinated polymerosome containing SAHA was fabricated for BC radiotherapy. The superior efficacy against BC cells when compared to free SAHA.…”

Section: Progress Of Nanocarrier‐based Research Toward Improved Deliv...mentioning

confidence: 99%

Current Strategies in Breast Cancer Therapy: Role of Epigenetics and Nanomedicine

Sengupta

Choudhury

Dutta

et al. 2022

Part & Part Syst Charact

View full text Add to dashboard Cite

Breast cancer (BC), the most common cancer in women, is incurable due to metastatic spread to distant organs. The existence of epigenetic dysregulation has been shown to contribute to the progression and even metastasize through the transition from epithelial to mesenchymal. Behind failure strategies of conventional treatments, fruitful outcomes of epigenetic drugs have provided the hope of solid tumor management where the reversal of acquired resistance of the cancer cells is possible by epigenome regulation. Several agents have been identified to target epigenetic regulators in the cancer cells exhibiting remarkable potential against solid tumors, including BC. However, unnecessary systemic exposure, solubility issues, and unsuitability for diseased conditions using conventional delivery systems limit their use as cancer therapeutics. The progression of nanotechnology in pharmaceutical delivery has revolutionized cancer therapy, where specific, targeted and efficient delivery of epigenetic agents for alteration of cancerous conditions are ensured. In this review, a focus is made on epigenetic alteration in BC condition with the deliverable potential of the nanocarriers toward the breast tumor microenvironment for proper management. The significance of targeting and controlled release of therapeutics in the improved targeting of cancer cells is highlighted.

show abstract

Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes

Cited by 47 publications

References 47 publications

Highly Antifungal Activity of Biosynthesized Copper Oxide Nanoparticles against Candida albicans

Highly Antifungal Activity of Biosynthesized Copper Oxide Nanoparticles against Candida albicans

In vitro and in vivo Evaluation of a Novel Estrogen-Targeted PEGylated Oxaliplatin Liposome for Gastric Cancer

Current Strategies in Breast Cancer Therapy: Role of Epigenetics and Nanomedicine

Contact Info

Product

Resources

About